Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
IGC Pharma (NYSE American: IGC) activated a new site for its Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's dementia at Tandem Clinical Research in Metairie, Louisiana.
Principal Investigator Dr. Angela Traylor will lead the site. Enrollment is reported as over 70% complete, and the addition aims to expand geographic reach and patient access.
IGC Pharma (NYSE American:IGC) announced a 12-part national media partnership with New to The Street to expand investor awareness across institutional and retail audiences. The campaign includes long-form televised interviews, national TV commercial distribution, digital amplification to a combined 4.45 million YouTube subscribers, and outdoor billboards in Times Square and the NYC Financial District.
The company said the multi-channel effort will run as a coordinated series of placements and curated investor events designed to raise visibility while the company remains focused on disciplined clinical execution and scientific development.
IGC Pharma (NYSE:IGC)/b) filed its Form 10-KT on March 19, 2026 for the nine months ended , reflecting a fiscal year change to December year-end.
Key points: Phase 2 CALMA enrollment surpassed 70%; net loss improved by $1.8M to $4.1M; $2.7M divestiture yielded ~$1.1M non-cash profit; R&D rose 48% to $4.0M; revenue was $869k. The company highlighted U.S. patents for IGC-AD1 formulation and a microdose cannabinoid, positive preclinical in-vitro data, AI awards, and plans to complete CALMA enrollment and pursue partnerships and AI monetization in FYE 2026.
IGC Pharma (NYSE:IGC) will demonstrate its Agentic Harmonization Assistant (AHA), an AI platform for automating harmonization and analysis of complex biomedical datasets, at ADPD 2026 in collaboration with the Alzheimer's Disease Data Initiative (ADDI).
AHA targets integration of clinical trial data, imaging, and other biomedical sources to reduce manual preparation time and support development of IGC-AD1 in the Phase 2 CALMA trial.
IGC Pharma (NYSE:IGC) announced on February 26, 2026 that it filed utility patent applications covering the architectural framework of its AI-based Agentic Harmonization Assistant (AHA). IGC says AHA standardizes heterogeneous Alzheimer's datasets; the company has harmonized 15 datasets and advanced AHA to a semi-final AI evaluation.
The filings aim to protect AHA's design and methodologies while IGC continues CALMA clinical trial work and plans additional AHA details at the upcoming ADPD conference.
IGC Pharma (NYSE American: IGC) announced that Ascendiant Capital Markets issued updated equity research coverage and raised its price target to $5.00 per share on February 24, 2026.
IGC noted analyst views are those of the analyst firm and provided a link to obtain the full report from Ascendiant Capital Markets.
IGC Pharma (NYSE:IGC) added Visionary Investigators Network (VIN) as a clinical research site for its Phase 2 CALMA trial of IGC-AD1 to treat agitation associated with Alzheimer's disease dementia. The company reported approximately 70% of planned enrollment is completed.
VIN's Coconut Grove site in Miami will support ongoing enrollment using a practice-integrated model and is led by Dr. Andrew Lerman with a dedicated clinical trial coordinator.
IGC Pharma (NYSE American: IGC) announced that the Canadian Intellectual Property Office issued a Notice of Allowance for patent No. 3,095,729, securing composition protection for IGC-AD1 across key North American jurisdictions.
IGC said the allowance covers the low-dose THC combination formulation as the Phase 2 CALMA trial approaches enrollment completion (≈70% enrolled).
IGC Pharma (NYSE American: IGC) will participate in a fireside chat hosted by Ascendiant Capital Markets on February 18, 2026 at 1:00 p.m. ET. CEO Ram Mukunda and CCO Claudia Grimaldi will discuss Phase 2 CALMA trial progress, enrollment momentum, regulatory developments, and the company’s AI-driven precision medicine platform.
The presentation will also cover progress across IGC’s broader pipeline of disease-modifying Alzheimer’s candidates and management’s fiscal 2026 milestones and strategic priorities.
IGC Pharma (NYSE American: IGC) announced that Alliance Global Partners published an updated equity research report on February 10, 2026. The report reiterates a Buy rating and sets a $3.00 price target per share. IGC disclaims endorsement and does not guarantee the report's accuracy.